Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021

Rhea-AI Summary

Sarepta Therapeutics (NASDAQ:SRPT) will announce its second quarter 2021 financial results after market close on August 4, 2021. A conference call is scheduled for 4:30 p.m. E.T. to discuss these results and provide a corporate update. Investors can access the call via phone or through the company's website, which will also archive the event for 90 days. Sarepta is focused on developing precision genetic medicine for rare diseases, particularly in Duchenne muscular dystrophy, with a robust pipeline of over 40 programs.

Positive

• Sarepta is a leader in precision genetic medicine, focusing on rare diseases.
• The company has over 40 programs in various stages of development.

Negative

• None.

CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2021 financial results and to provide a corporate update.

The conference call may be accessed by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers. The passcode for the call is 8374717. Please specify to the operator that you would like to join the "Sarepta Second Quarter 2021 Earnings Call." The conference call will be webcast live under the investor relations section of Sarepta.com and will be archived there following the call for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Sarepta Therapeutics
Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development. Our vast pipeline is driven by our multi-platform Precision Genetic Medicine Engine in gene therapy, RNA and gene editing. For more information, please visit www.sarepta.com or follow us on Twitter, LinkedIn, Instagram and Facebook.

Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.

Source: Sarepta Therapeutics, Inc.

Investor Contact:
Ian Estepan, 617-274-4052
iestepan@sarepta.com 

Media Contact:
Tracy Sorrentino, 617-301-8566
tsorrentino@sarepta.com 

FAQ

When will Sarepta Therapeutics report its second quarter 2021 financial results?

Sarepta will report its second quarter 2021 financial results on August 4, 2021, after market close.

What time is the Sarepta second quarter 2021 earnings call scheduled?

The earnings call is scheduled for 4:30 p.m. E.T. on August 4, 2021.

How can investors access the Sarepta earnings call?

Investors can access the earnings call by dialing (844) 534-7313 for domestic callers and (574) 990-1451 for international callers.

What is Sarepta Therapeutics' focus in the pharmaceutical industry?

Sarepta focuses on precision genetic medicine for rare diseases, primarily Duchenne muscular dystrophy.

What type of programs does Sarepta Therapeutics have in development?

Sarepta has more than 40 programs in various stages of development targeting rare diseases.